Tag: Combination Strategies
Advances, Sequencing Challenges, and Real-World Integration of ADCs in Breast Cancer:...
Advances, Sequencing Challenges, and Real-World Integration of ADCs in Breast Cancer: Insights from ASCO 2026
Next-Generation Antibody-Drug Conjugates: Sutro’s Robust Preclinical Activity and Platform Innovations
Recent advances in antibody-drug conjugate (ADC) technology have enabled the development of highly potent, tumor-targeted therapeutics with improved efficacy and safety. Sutro Biopharma, leveraging its site-specific and cell-free protein synthesis platform, has reported robust preclinical data for its pipeline of next-generation ADCs at the annual meeting of the American Association for Cancer Research (AACR), held April 17 - 22, 2026.
